Recent News

• 03.30.2026 - IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma
• 03.27.2026 - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 03.22.2026 - IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial
• 03.18.2026 - IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs
• 03.09.2026 - IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update
• 02.27.2026 - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 02.25.2026 - IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC
• 02.23.2026 - IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer
• 02.17.2026 - IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
• 02.02.2026 - IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events

Recent Filings

• 03.27.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 03.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.17.2026 - 8-K Current report
• 02.17.2026 - EX-99.1 EX-99.1
• 02.17.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.17.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.17.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 02.12.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.02.2026 - 4 Statement of changes in beneficial ownership of securities